000283060 001__ 283060
000283060 005__ 20251229124832.0
000283060 0247_ $$2doi$$a10.1016/j.cell.2025.11.033
000283060 0247_ $$2pmid$$apmid:41448139
000283060 0247_ $$2ISSN$$a0092-8674
000283060 0247_ $$2ISSN$$a1097-4172
000283060 037__ $$aDZNE-2025-01467
000283060 041__ $$aEnglish
000283060 082__ $$a610
000283060 1001_ $$aCourade, Jean-Philippe$$b0
000283060 245__ $$aThe evolving landscape of Alzheimer's disease therapy: From Aβ to tau.
000283060 260__ $$a[Cambridge, Mass.]$$bCell Press$$c2025
000283060 3367_ $$2DRIVER$$aarticle
000283060 3367_ $$2DataCite$$aOutput Types/Journal article
000283060 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767008744_31206$$xReview Article
000283060 3367_ $$2BibTeX$$aARTICLE
000283060 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283060 3367_ $$00$$2EndNote$$aJournal Article
000283060 520__ $$aA marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.
000283060 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283060 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283060 650_7 $$2Other$$aA(I)TN
000283060 650_7 $$2Other$$aASO
000283060 650_7 $$2Other$$aAT(X)N
000283060 650_7 $$2Other$$aATN
000283060 650_7 $$2Other$$aAbeta therapy
000283060 650_7 $$2Other$$aAlzheimer's disease
000283060 650_7 $$2Other$$aPET imaging
000283060 650_7 $$2Other$$aamyloid
000283060 650_7 $$2Other$$aanti-sense oligonucleotides
000283060 650_7 $$2Other$$aclinical trial
000283060 650_7 $$2Other$$aimmunization
000283060 650_7 $$2Other$$ainflammation
000283060 650_7 $$2Other$$aneurodegeneration
000283060 650_7 $$2Other$$anext-generation therapies
000283060 650_7 $$2Other$$atau
000283060 650_7 $$2Other$$atau therapy
000283060 650_7 $$2Other$$atauopathies
000283060 650_7 $$2Other$$atherapy development
000283060 650_7 $$2Other$$atrial
000283060 650_7 $$2NLM Chemicals$$atau Proteins
000283060 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000283060 650_2 $$2MeSH$$aAlzheimer Disease: therapy
000283060 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000283060 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000283060 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000283060 650_2 $$2MeSH$$aHumans
000283060 650_2 $$2MeSH$$atau Proteins: metabolism
000283060 650_2 $$2MeSH$$atau Proteins: antagonists & inhibitors
000283060 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000283060 650_2 $$2MeSH$$aAmyloid beta-Peptides: antagonists & inhibitors
000283060 650_2 $$2MeSH$$aImmunotherapy: methods
000283060 650_2 $$2MeSH$$aAnimals
000283060 650_2 $$2MeSH$$aClinical Trials as Topic
000283060 7001_ $$aZetterberg, Henrik$$b1
000283060 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b2$$udzne
000283060 7001_ $$aDewachter, Ilse$$b3
000283060 773__ $$0PERI:(DE-600)2001951-8$$a10.1016/j.cell.2025.11.033$$gVol. 188, no. 26, p. 7337 - 7354$$n26$$p7337 - 7354$$tCell$$v188$$x0092-8674$$y2025
000283060 8564_ $$uhttps://pub.dzne.de/record/283060/files/DZNE-2025-1467.pdf$$yRestricted
000283060 8564_ $$uhttps://pub.dzne.de/record/283060/files/DZNE-2025-1467.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283060 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283060 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283060 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-01$$wger
000283060 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL : 2022$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000283060 915__ $$0StatID:(DE-HGF)9960$$2StatID$$aIF >= 60$$bCELL : 2022$$d2025-01-01
000283060 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000283060 980__ $$ajournal
000283060 980__ $$aEDITORS
000283060 980__ $$aVDBINPRINT
000283060 980__ $$aI:(DE-2719)1111015
000283060 980__ $$aUNRESTRICTED